[1]
|
Kao, J.H. and Chen, D.S. (2002) Global control of hepatitis B virus infection. The Lancet Infectious Diseases, 2, 395-403. doi:10.1016/S1473-3099(02)00315-8
|
[2]
|
Lok, A.S., Lai, C.L., Leung, N. and Yao, G.B. (2003) Long term safety of Lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125, 1714- 1722. doi:10.1053/j.gastro.2003.09.033
|
[3]
|
Tziomalos. K. (2009) Combination treatment in HBe-Ag negative chronic hepatitis B. World Journal of Hepatology, 1, 43-47. doi:10.4254/wjh.v1.i1.43
|
[4]
|
Peters, M.G., Hann, H.H., Martin, P. and Heathcote, E.J. (2004) Adefovir dipivoxil alone or in combination with Lamivudine in patients with Lamivudine-resistant chronic hepatitis B. Gastroenterology, 126, 91-101.
doi:10.1053/j.gastro.2003.10.051
|
[5]
|
Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J. and Chang, T.T. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. The New England Journal of Medicine, 348, 800-807.
doi:10.1056/NEJMoa021812
|
[6]
|
Perrillo, R., Hann, H.W., Mutimer, D. and Willems, B. (2004) Adefovir dipivoxil added to ongoing Lamivudine in chronic hepatitis B with YMDD mutant hepatitis B vi- rus. Gastroenterology, 126, 81-90.
doi:10.1053/j.gastro.2003.10.050
|
[7]
|
Lui, C.J., Kao, J.H., Chen, P.J. and Chen, T.C. (2006) Overlap Lamivudine treatment in patients with chronic hepatitis B receiving Adefovir for Lamivudine-resistant viral mutants. Journal of Viral Hepatitis, 13, 387-395.
doi:10.1111/j.1365-2893.2005.00704.x
|
[8]
|
Akyildiz, M., Gunsar, F., Ersoz, G. and Karasu, Z. (2007) Adefovir dipivoxil alone or in combination with Lamivudine resistant compensated chronic hepatitis B. Digestive Diseases and Sciences, 52, 3444-3447.
doi:10.1007/s10620-006-9718-8
|
[9]
|
Rapti, I., Dimou, E., Mitsoula, P. and Hadziyannis, S.J. ( 2007) Adding-on versus switching-to adefovir therapy in Lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology, 45, 307-313. doi:10.1002/hep.21534
|
[10]
|
Hosaka, T., Suzuk, F., Suzuki, Y. and Saithoh, S. (2004) Adefovir dipivoxil for treatment of breakthrough hepatitis caused by Lamivudine-resistant mutants of hepatitis B virus. Intervirology, 47, 362-369. doi:10.1159/000080881
|
[11]
|
Buti, M., Elefsitionis, I., Jardi, R. and Vargas, V. (2007) Viral genotype and baseline load predict the response to Adefovir treatment in Lamivudine-resistant chronic heaptitis B patients. Journal of Hepatology, 47, 366-372.
doi:10.1016/j.jhep.2007.04.011
|
[12]
|
Lampertico, P., Vigano, M., Manenti, E. and Lavarone, M. (2007) Low resistance to Adefovir combined with Lamivudine: A 3-year study of 145 Lamivudine-resistant hepatitis B patients. Gastroenterology, 133, 1445-1451.
doi:10.1053/j.gastro.2007.08.079
|
[13]
|
Bommel, F.V., Wunsche, T., Mauss, S. and Reinke, P. (2004) Comparison of adefovir and tenofovir in the treat- ment of Lamivudine-resistant hepatitis B virus infection. Hepatology, 40, 1421-1425. doi:10.1002/hep.20464
|
[14]
|
Bommel, F.V., Zollner, B., Sarrazin, C. and Spengler, U. (2006) Tenofovir for patients with Lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during Adefovir therapy. Hepatology, 44, 318-325.
doi:10.1002/hep.21253
|
[15]
|
Lampertico, P., Vigano, M., Manenti, E. and Lavarone, M. (2005) Adefovir rapidly suppresses hepatitis B in HBe-Ag negative patients developing genotypic resistance to Lamivudine. Hepatology, 42, 1414-1419.
doi:10.1002/hep.20939
|
[16]
|
Westland, C.E., Yang, H., Delaney, W.E. and Wulfsohn, M. (2005) Activity of Adefovir dipivoxil against all patterns of Lamivudine-resistant hepatitis B viruses in patients. Journal of Viral Hepatitis, 12, 67-73.
|